A review of the JR blood group system by Castilho, Lilian & Reid, Marion E.
IMMUNOHEMATOLOGY, Volume 29, Number 2, 2013 63
A review of the JR blood group system
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The JR blood group system (ISBT 032) consists of one antigen, 
Jra, which is of high prevalence in all populations. The rare 
Jr(a–) phenotype has been found mostly in Japanese and other 
Asian populations, but also in people of northern European 
ancestry, in Bedouin Arabs, and in one Mexican. Anti-Jra has 
caused transfusion reactions and is involved in hemolytic 
disease of the fetus and newborn. The Jra antigen is located on 
ABCG2 transporter, a multipass membrane glycoprotein (also 
known as the breast cancer resistance protein, BCRP), which 
is encoded by the ABCG2 gene on chromosome 4q22.1. The 
Jr(a–) phenotype mostly results from recessive inheritance of 
ABCG2 null alleles caused by frameshift or nonsense changes. 
Immunohematology 2013;29:63–68.
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History
The high-prevalence erythrocyte blood group antigen 
Jra was first reported in 1970 by Stroup and MacIlroy1 at the 
23rd annual meeting of the American Association of Blood 
Banks, when it was recognized that five individuals had 
an antibody to the same antigen, present on all erythrocyte 
samples tested except those from each other. This new 
alloantibody—called anti-Jra, defining a “new” blood group 
antigen of high prevalence (named Jr after Rose Jacobs, one 
of the first five probands, and not an abbreviation of “Junior” 
as some believed)—showed no relation with any other blood 
group system. By 1974, Gellerman and Stroup2 had identified 
18 examples of anti-Jra, 7 of which had been made by Japanese 
people.
In 1994, Miyazaki and colleagues3 published the isolation 
and characterization of an immunoglobulin G3 (IgG3) 
human monoclonal anti-Jra (HMR0921) produced by a 
heterohybridoma derived from mouse myeloma cells and 
Epstein-Barr virus (EBV)–transformed lymphocytes from 
a blood donor with anti-Jra. Using this human monoclonal 
antibody, the authors found a prevalence of 0.07 percent for 
the Jr(a–) phenotype in the Japanese blood donors. Nakajima 
and Ito4 and Okubo5 previously reported that the prevalence 
of the Jr(a–) phenotype in Japan was 0.03 and 0.12 percent, 
respectively. Other studies6–10 have shown that the rare Jr(a–) 
phenotype occurs in various populations (northern European 
extraction, Bedouin Arabs, and one Mexican) but is found 
most often in Japanese and other people of Asian ancestry.
Anti-Jra is stimulated by either transfusion or pregnancy. 
A review of the literature indicates that anti-Jra may be clini-
cally significant because it has been implicated in cases of 
hemolytic disease of the fetus and newborn (HDFN)4,6,8,11–21 
and hemolytic transfusion reactions (HTRs).22–28 Anti-
Jra has caused significant transfusion reactions as well as 
severe HDFN in some cases,15–18 including two cases of fatal 
HDFN.17,18
In 1990, the Jra antigen was placed in the 901 series of 
high-incidence antigens by the International Society of Blood 
Transfusion (ISBT) and assigned #901005.29
For many years, numerous laboratories using various 
methods have failed to characterize Jra, and their attempts to 
immunoprecipitate and immunoblot the antigen using human 
anti-Jra were unsuccessful.
The rare Jr(a–) phenotype appeared to be inherited as an 
autosomal recessive trait as the children of Jr(a+) parents type 
Jr(a–),2 but the gene controlling the expression of Jra was not 
known until two recent studies30,31 that provided genetic and 
molecular evidence that null alleles in ABCG2 define the Jr(a–) 
phenotype.
Jr Is Carried on ABCG2 Transporter and Encoded 
by ABCG2 Gene
Recently, in an attempt to identify the gene responsible 
for Jra expression, two groups using different approaches30,31 
established the connection between the Jr(a–) blood group 
phenotype and ABCG2.
Zelinski and coworkers30 conducted a homozygosity-by-
descent (HBD) mapping study to identify the chromosomal 
region containing the gene responsible for Jra expression. 
Genomic DNA was extracted from stored samples of six Jr(a–) 
individuals (four probands). The authors performed analysis 
of single nucleotide polymorphisms (SNPs), (GeneChip 
Human Mapping, 250K Nsp array, Affymetrix, Santa Clara, 
CA)  and identified a homozygous region of 397,000 bp located 
at chromosome 4q22.1 that contained four validated genes: 
MEPE, SPPI, PKD2, and ABCG2, but only the product of 
ABCG2 was known to be expressed on red blood cells (RBCs). 
DNA sequence analysis defined three nonsense ABCG2 alleles 
(c.376C>T, c.706C>T, and c.736C>T) in the six study subjects 
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(Table 1). The nonsense mutation c.736C>T was 
present in homozygous state in two subjects and 
the nonsense mutation c.376C>T was present 
in homozygous state in three subjects. The 
remaining individual was homozygous for the 
missense c.34G>A mutation and heterozygous for 
the nonsense mutation c.706C>T.
This study,30 the first to use an HBD gene 
mapping strategy to identify a gene for a blood 
group system, provided genetic proof that the 
Jr(a–) phenotype is defined by the ABCG2 null 
allele.
Because HMR0921 monoclonal antibody 
(MoAb)3 reacted weakly with RBCs from humans, 
Saison and coworkers31 explored the existence of 
Jra in different mammalian species by analyzing 
their RBCs by flow cytometry using HMR0921. 
They observed that cat RBCs reacted much more 
strongly than human RBCs and decided to identify 
the antigen recognized by the HMR0921 MoAb 
on cat RBCs. Using a lysate from cat RBCs, they 
immunoprecipitated a single protein of around 70 
kDa, identified by mass spectrometry as abcg2, 
encoded by the cat ortholog (abcg2) of the human 
transporter gene ABCG2. They transfected K-562 
cells with ABCG2 and observed strong expression 
of ABCG2 as well as Jra at the surface of the ABCG2-
transfected K-562 cells. Using these cells to immunoprecipitate 
ABCG2 with the HMR0921, they verified expression of Jra on 
RBCs and concluded that Jra is carried on ABCG2. Further 
studies including Western blot analysis proved that ABCG2 
was absent in the RBC membrane of Jr(a–) individuals. 
Sequencing of ABCG2 in a cohort of 18 unrelated Jr(a–) 
probands identified eight different mutations in ABCG2: 
five frameshift mutations (c.187_197delATATTATCGAA, 
c.542_543insA, c.791_792delTT, c.875_878dupACTT, 
c.1111_1112delAC) and three nonsense mutations (c.376C>T, 
c.706C>T, c.730C>T; Table 1). Interestingly, later the 
nonsense mutation c.706C>T was reported to be present 
in the homozygous state in six of seven Gypsy subjects and 
in the heterozygous state in the seventh Gypsy subject, 
suggesting that this nucleotide change is the basis of the Jr(a–) 
phenotype in this ethnic group.31 Similarly, the nonsense 
mutation c.376C>T was present in the homozygous state in 
three unrelated Jr(a–) subjects from Korea, suggesting this 
is a founder mutation, too. Actually, this mutation has been 
extensively studied as a nonsynonymous SNP of ABCG2 
(rs72552713) in the Japanese population with an estimated 
allele frequency of 1.6 to 2.4 percent.34,35 These are important 
data to be considered for implementation in RBC genotyping 
devices.
The reports of Zelinski et al.30 and Saison et al.,31 published 
42 years after the first examples of anti-Jra, provided the 
information that Jra is carried on the ABCG2 transporter 
and encoded by the ABCG2 gene. Based on these results, 
Jra, previously designated ISBT 901.005, was promoted 
from the 901 series of high-incidence antigens to a blood 
group system (JR or ISBT 032) by the ISBT Working Party 
on Red Cell Immunogenetics and Blood Group Terminology 
in July 2012 (www.isbtweb.org/, Working Party on Red Cell 
Immunogenetics, J.R. Storry, personal communication, 2012).
ABCG2 Gene and ABCG2 Glycoprotein
ABCG2 is located on chromosome 4q22.1. It is composed 
of 16 exons (15 coding exons) that span approximately 68.6 
kb of gDNA. The gene encodes a 655–amino acid, 72.6-kDa 
ABCG2 protein.36 The amino acid sequence of the wild-type 
ABCG2 protein is shown in Figure 1.
Table 1. Alleles encoding Jr(a–) and Jr(a+W/–) phenotypes
Phenotype Nucleotide change (exon) Amino acid Ethnicity*
Jr(a–) c.376C>T (4) Gln126Stop Asian30,31
Jr(a–) c.706C>T (7) Arg236Stop Caucasian30
Jr(a–) c.34G>A (2), c.706C>T (7) Va112Met, 
Arg236Stop
Asian30
Jr(a–) c.736C>T (7) Arg246Stop Caucasian30
Jr(a–) c.337C>T (4) Arg113stop Caucasian32
Jr(a–) c.784G>T (7) Gly262Stop Caucasian32
Jr(a–) c.34G>A (2), 1591C>T (13) Va112Met, 
Gln531Stop
Caucasian32
Jr(a–) c.187_197delATATTATCGAA (2) Ile63TyrfsStop54 Caucasian31
Jr(a–) c.542_543insA (6) Phe182ValfsStop14 Caucasian31
Jr(a–) c.730C>T (7) Gln244Stop Caucasian31
Jr(a–) c.791_792delTT (7) Leu264HisfsStop14 Caucasian31
Jr(a–) c.875_878dupACTT (8) Phe293LeufsStop8 Caucasian31
Jr(a–) c.1111_1112delAC (9) Thr371LeufsStop20 Asian31
Jr(a–) c.34G>A(2), c.244_245insC (3) Va112Met, 
Thr82HisfsStop38
Asian30,32
Jr(a–) c.1017_1019delCTC (9) Ser340del Caucasian33
Jr(a+W/–) c.421C>A (4) Gln141Lys Caucasian33
Jr(a+W/–) c.1858G>A (16) Asp620Asn Caucasian33
Jr(a+W/–) c.1714A>C (16) Ser572Arg Caucasian33
*Most alleles have been found in only one proband. The exceptions are c.376C>T, which 
has been found in Japanese, Koreans, and Chinese, and c.706C>T, which has been found 
in Gypsies and in one Asian with a concomitant c.34G>A.30,31
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ABCG2 (breast cancer resistance protein [BCRP], 
mitoxantrone resistance protein), a well-studied molecule 
with more than 2000 publications, is an abbreviation for 
ATP-binding cassette (ABC), subfamily G, member 2. ABC 
transporters form one of the largest protein families encoded 
in the human genome, and more than 48 human ABC protein 
genes have been identified.37 ABCG2 is predicted to pass 
through the membrane six times and has a single N-linked 
glycan. The intracellular amino terminal harbors a nucleotide-
binding domain with Walker A, Walker B, and ABC signature 
motifs.38 The functional molecule is likely a homodimer or 
homotetramer in the membrane.39,40 Figure 2 depicts the 
predicted structure of the ABCG2 protein in the membrane 
and shows the location of amino acid changes encoded by 
nonsense and missense alleles.
ABCG2 has high expression in the placenta and blood–
brain barrier and has low expression in epithelial cells of small 
and large intestines, liver ducts, colon, and lobes of the breast, 
in endothelial cells of veins and capillaries, in brain microvessel 
endothelium, and in stem cells, lung, and the apical membrane 
of proximal tubules of the kidney.38,41,42
Functional Aspects of the ABCG2 Glycoprotein
Numerous studies in Abcg2–/– mice have suggested roles 
for ABCG2 in a variety of physiologic processes. ABCG2, also 
named BCRP, is known to be an essential transporter in cell 
detoxification and has a wide variety of substrates.41–44 It is 
a high-capacity transporter of urate,38,45 it appears to have a 
role in folate46 and porphyrin homeostasis,47,48 it may protect 
normal cells from toxic agents or metabolites,49 it may play a 
role in removing xenobiotics from the brain,50 and it may be 
involved in brain-to-blood efflux.51 It transports a wide variety 
of drugs and does not require glutathione for transport of 
electroneutral amphipathic compounds.52 It also appears to 
play a major role in the multidrug resistance phenotype of 
several cancer cell lines and solid tumors, posing a problem in 
chemotherapy.53,54 The Gln126Stop and Gln141Lys variants of 
ABCG2 are associated with an increased risk for gout.55 In a 
recent paper, Tiribelli et al.56 demonstrated that the Gln141Lys 
variant is associated with poor outcome in patients with acute 
myeloid leukemia receiving idarubicin-based chemotherapy.
Molecular Bases of Jr(a–) and Jr(a+W/–) 
Phenotypes
The Jr(a–) phenotype results from the recessive 
inheritance of ABCG2 null mutations caused by frameshift or 
nonsense changes, and the Jr(a+W/–) phenotype results from 
missense nucleotide changes (Table 1, Fig. 2).32,33
Jra Antigen
Jra is fully developed on cord blood cells. The antigen 
is resistant to the treatment of RBCs with papain, 
trypsin, chymotrypsin, pronase, neuraminidase, and 
2-aminoethylisothiouronium bromide.57
Clinical Significance
Anti-Jra is generally IgG (some are IgG1; some are a 
mixture of IgG1 and IgG3) and reacts best by the antiglobulin 
test, especially when ficin- or papain-treated RBCs are used.57 
IgM anti-Jra was found in the plasma of two Jr(a–) brothers 
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Fig. 1 Amino acid sequence of ABCG2 protein. Amino acid 
sequence taken from GenBank, accession NP_004818.2.
Fig. 2 Predicted topology of ABCG2 protein with location of amino 
acid changes encoded by nonsense and missense alleles. The 
single-letter code is used for amino acids. RBC = red blood cell; 
–S– = disulfide bond; X = stop codon.
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untransfused Jr(a–) women during their first pregnancy.12,13 
Some anti-Jra may bind complement.4,9,57 A collaborative study 
of irregular erythrocyte antibodies in Japan showed that anti-
Jra is more frequently determined in pregnant patients than in 
nonpregnant patients.58
Anti-Jra may be stimulated by transfusion22 or by 
pregnancy.7,10 Rare cases of hemolysis associated with trans-
fusion have been reported, mostly as delayed HTRs.7,22–26 One 
patient with anti-Jra in the plasma developed rigors after 150 
mL of serologically incompatible blood had been transfused,24 
and in another patient chromium-51 cell survival studies 
indicated reduced RBC survival.7 In contrast, another patient 
with anti-Jra was transfused with three units of Jr(a+) blood 
in an emergency situation,13 and no symptoms of either an 
immediate or a delayed HTR were seen, although the titer 
of anti-Jra increased from 32 to 2048 on the 20th day after 
transfusion and later fell to 64 (35 days after transfusion). 
Kwon et al.27 described two cases of anti-Jra in the setting of 
incompatible transfusions, one without consequences despite 
multiple transfusions of Jr(a+) blood and the other leading to 
an acute HTR. Ogasawara and Mazuda59 studied 20 plasma 
samples containing anti-Jra and reported that none mediated 
phagocytosis of RBCs (in vitro). Garratty et al.60 reported that 
only one of eight anti-Jra samples had a positive monocyte 
monolayer assay, suggesting clinical significance.
Anti-Jra has been responsible for a positive direct 
antiglobulin test on RBCs from newborns and, rarely, 
HDFN.4,9,12,13 A review of the literature indicates that anti-
Jra has caused mild and even severe cases of HDFN with no 
evidence of hemolysis.11–21 There is one report of a fatality 
associated with anti-Jra alloimmunization.17 Collectively, these 
data suggest that Jra, like Kell and Gerbich,61,62 is expressed on 
erythroid progenitor cells and that in these cases of HDFN, 
anti-Jra causes suppression of erythropoiesis rather than 
hemolysis.
Concluding Remarks
To date, nearly 1300 synonymous and nonsynonymous 
SNPs in the gene sequence of ABCG2 have been described 
(http://www.ncbi.nlm.nih.gov/snp), and therefore, additional 
diversity within the JR blood group system is still expected.
Jr(a–) individuals provide a large cohort of “natural 
knockouts” for ABCG2 (ABCG2–/–), opening the opportunity 
to study the exact role and function of ABCG2 in humans 
under normal physiology and in pathologic conditions such as 
cancer.
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